Page last updated: 2024-08-24

nelfinavir and Neoplasms

nelfinavir has been researched along with Neoplasms in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (42.86)	29.6817
2010's	8 (57.14)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davies, DM; Dunlop, EA; Errington, RJ; Giles, PJ; Hay, T; Johnson, CE; Jones, AT; McCann, HD; Parfitt, GJ; Sampson, JR; Seifan, S; Shen, MH; Tee, AR	1
Ambinder, RF; Casper, C; Gantt, S	1
Brüning, A; Friese, K; Rahmeh, M	1
Ballas, MS; Bernstein, WB; Blumenthal, GM; Chun, G; Dechowdhury, R; Dennis, PA; Figg, WD; Gardner, ER; Gills, JJ; Helsabeck, C; Kawabata, S; Komiya, T; LoPiccolo, J; Morrow, B; Root, H; Steinberg, SM	1
Boettiger, DC; Bonnet, F; Bower, M; Fätkenheuer, G; Grulich, A; Kirk, O; Law, M; Lundgren, JD; Monforte, Ad; Phillips, A; Reiss, P; Ryom, L; Sabin, CA	1
De Gassart, A; Demaria, O; Gilliet, M; Martinon, F; Panes, R; Ryazanov, AG; Zaffalon, L	1
Chow, WA; Guan, M; Jiang, C	1
Agan, B; Barthel, RV; Crum-Cianflone, NF; Fraser, S; Ganesan, A; Hullsiek, KH; Marconi, V; Roediger, MP; Wegner, S; Weintrob, A	1
Gocke, E; Lavé, T; Müller, L; Pfister, T	1
Bürgin, H; Gocke, E; Müller, L; Pfister, T	1
Brüning, A; Friese, K; Gingelmaier, A; Mylonas, I	1
Brüning, A	1
Ahmed, MS; Cerniglia, GJ; Feldman, MD; Frank, I; Gudonis, D; Gupta, AK; Plastaras, JP; Vapiwala, N	1
Bernhard, EJ; Brunner, TB	1

Reviews

4 review(s) available for nelfinavir and Neoplasms

Article	Year
Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. Current opinion in oncology, 2013, Volume: 25, Issue:5 Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; HIV Protease Inhibitors; Humans; Nelfinavir; Neoplasms; Proto-Oncogene Proteins c-akt	2013
Anti-HIV drugs for cancer therapeutics: back to the future? The Lancet. Oncology, 2009, Volume: 10, Issue:1 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cidofovir; Cytosine; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Neoplasms; Organophosphonates; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine	2009
Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents, Alkylating; DNA; DNA Damage; Dose-Response Relationship, Drug; Drug Contamination; Ethyl Methanesulfonate; Female; HIV Protease Inhibitors; Humans; Male; Mice; Nelfinavir; Neoplasms; No-Observed-Adverse-Effect Level; Rats; Reproduction; Risk Assessment; Toxicity Tests	2009
New prospects for nelfinavir in non-HIV-related diseases. Current molecular pharmacology, 2010, Volume: 3, Issue:2 Topics: Anti-HIV Agents; Anti-Infective Agents; Antineoplastic Agents; Apoptosis; Humans; Nelfinavir; Neoplasms	2010

Trials

1 trial(s) available for nelfinavir and Neoplasms

Article	Year
A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. Oncotarget, 2014, Sep-30, Volume: 5, Issue:18 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; HIV Protease Inhibitors; Humans; Male; Maryland; Maximum Tolerated Dose; Middle Aged; Nelfinavir; Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Young Adult	2014

Article

Year

A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors.

Oncotarget, 2014, Sep-30, Volume: 5, Issue:18

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; HIV Protease Inhibitors; Humans; Male; Maryland; Maximum Tolerated Dose; Middle Aged; Nelfinavir; Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Young Adult

2014

Other Studies

9 other study(ies) available for nelfinavir and Neoplasms

Article	Year
Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death. Oncogene, 2018, Volume: 37, Issue:45 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum Stress; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Nelfinavir; Neoplasms; Tuberous Sclerosis Complex 2 Protein; Xenograft Model Antitumor Assays	2018
Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation. Molecular oncology, 2013, Volume: 7, Issue:6 Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; HIV Protease Inhibitors; Humans; Nelfinavir; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Pyrazines; TOR Serine-Threonine Kinases; Up-Regulation	2013
Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? AIDS (London, England), 2016, 06-19, Volume: 30, Issue:10 Topics: Adult; Carcinogens; Cohort Studies; Drug Contamination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Male; Middle Aged; Nelfinavir; Neoplasms; Risk Assessment	2016
Pharmacological eEF2K activation promotes cell death and inhibits cancer progression. EMBO reports, 2016, Volume: 17, Issue:10 Topics: AMP-Activated Protein Kinases; Animals; Cell Death; Cell Line; Cell Survival; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance; Elongation Factor 2 Kinase; Female; Gene Expression; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Multiprotein Complexes; Nelfinavir; Neoplasms; Peptide Elongation Factor 2; Phosphorylation; Protein Biosynthesis; TOR Serine-Threonine Kinases; Tumor Burden	2016
The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. Journal of acquired immune deficiency syndromes (1999), 2009, Jul-01, Volume: 51, Issue:3 Topics: Adult; Anticarcinogenic Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Neoplasms; Proportional Hazards Models; Retrospective Studies; Risk	2009
Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Alkylating Agents; Animals; Dose-Response Relationship, Drug; Drug Contamination; Environmental Exposure; Ethyl Methanesulfonate; HIV Protease Inhibitors; Humans; Mice; Mutagens; Mutation; Nelfinavir; Neoplasms; No-Observed-Adverse-Effect Level; Rats; Reproduction; Risk Assessment; Toxicity Tests	2009
Analysis of nelfinavir-induced endoplasmic reticulum stress. Methods in enzymology, 2011, Volume: 491 Topics: Animals; Cell Line, Tumor; Endoplasmic Reticulum; HIV Protease Inhibitors; Humans; Immunoblotting; Microscopy, Fluorescence; Microscopy, Phase-Contrast; Nelfinavir; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction	2011
Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer biology & therapy, 2008, Volume: 7, Issue:5 Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Biomarkers, Tumor; Female; HIV Protease Inhibitors; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Nelfinavir; Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents	2008
Progress towards the use of HIV protease inhibitors in cancer therapy. Cancer biology & therapy, 2008, Volume: 7, Issue:5 Topics: Biomarkers, Tumor; Clinical Trials as Topic; HIV Protease Inhibitors; Humans; Leukocytes, Mononuclear; Nelfinavir; Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents	2008